echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > China CDC released the monitoring of adverse reactions of my country's new crown vaccination for the first time, with a reported incidence of 11.86 per 100,000 doses

    China CDC released the monitoring of adverse reactions of my country's new crown vaccination for the first time, with a reported incidence of 11.86 per 100,000 doses

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    href="" target="_blank" rel="noopener"> May 28, according to the latest news on the adverse reaction report of the immunization program on the official website of the China Center for Disease Control and Prevention , from December 15, 2020 to April 30, 2021, 31 provinces, municipalities, autonomous regions, and Xinjiang Production and Construction Corps reported vaccination against the new crown virus.


    Immunization prevention

    Among the adverse reactions, 26,078 were general reactions, accounting for 82.


    Blood vessel

    The Chinese Center for Disease Control and Prevention has released a detailed interpretation of the monitoring information on adverse reactions of the new crown vaccination nationwide .


    Interpretation of the general reaction and abnormal reaction rate of China's new coronavirus vaccine are lower than the average reported level of other types of vaccines in China in 2019.


    About 40% of subjective symptoms such as dizziness, fatigue, or nausea are reported in general reactions.


    Most of them also have systemic symptoms such as pain, redness and swelling at the injection site, fever, headache, nausea, diarrhea, fatigue, and limb pain.


    New Coronary Pneumonia Infection

    China’s Disease Control and Prevention stated that China has started mass population vaccination on December 15, 2020.


    Inactivated vaccines, adenovirus vector vaccines (type 5 adenovirus vectors), recombinant subunit vaccines (CHO cells) and other vaccines with different technical routes have been used in emergency domestically or approved for marketing with conditions.
    Inactivated vaccines, adenovirus vector vaccines (type 5 adenovirus vectors), recombinant subunit vaccines (CHO cells) and other vaccines with different technical routes have been used in emergency domestically or approved for marketing with conditions.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.